CDF-Peds-LC™: A Composite Diagnostic Fingerprint for Pediatric Long COVID
- Mar 15
- 29 min read
This paper is part of the CYNAERA Long COVID Library, a growing resource, impacting how infection associated chronic conditions are researched, treated and understood. It is occasionally updated as new research comes out.
By Cynthia Adinig
Introduction
Pediatric Long COVID is not merely a diagnostic blind spot. It is a systems-recognition failure occurring at the intersection of post-infectious chronic disease, developmental variability, fragmented pediatric documentation, and institutional overreliance on narrow behavioral or psychosomatic explanations. The field has moved well beyond the question of whether prolonged post-COVID illness occurs in children. Major federal and academic work now recognizes Long COVID as an infection-associated chronic condition that can be continuous, relapsing and remitting, or progressive, and pediatric studies from the RECOVER initiative have shown that symptom patterns differ across early childhood, school age, and adolescence rather than following a single uniform template (National Academies of Sciences, Engineering, and Medicine, 2024; Gross et al., 2024; Gross et al., 2025).
The scale of pediatric burden is substantial even under conservative federal accounting, and likely far larger under broader clinical modeling. CDC materials state that, as of 2023, roughly 1 million U.S. children ages 5 to 17 had experienced Long COVID, while the 2022 National Health Interview Survey estimated that 1.3% of U.S. children had ever had Long COVID and 0.5% currently had it at the time of interview (Vahratian et al., 2023; CDC, 2025). A major Pediatrics review further noted that prevalence assumptions in the range of 10% to 20% could translate to as many as 5.8 million affected children in the United States (Rao et al., 2024). Building on this literature, CYNAERA’s current U.S. pediatric burden model estimates that approximately 6 to 10 million children may be living with pediatric Long COVID or functionally comparable post-COVID illness, reflecting the likelihood that existing surveillance approaches undercount relapsing, multisystem, underdiagnosed, and intermittently disabling cases. This range should therefore be understood as a burden estimate rather than a narrow confirmed-case count.
The problem is not simply that children have symptoms. The problem is that many present in ways pediatric systems are poorly trained to interpret. Fatigue, cognitive slowing, headaches, dizziness, sensory overwhelm, sleep disruption, orthostatic symptoms, gastrointestinal changes, and exertion-linked crashes may be distributed across home, school, therapy, and primary care rather than captured in one neat subspecialty note. Consensus work in children and young people has already highlighted domains such as post-exertional malaise, cardiovascular effects, and school or study change as core outcomes relevant to pediatric post-COVID condition, yet those domains are still inconsistently translated into frontline diagnostic logic (Seylanova et al., 2024).
CDF-Peds-LC™ was developed as CYNAERA's proposed Composite Diagnostic Fingerprint for Pediatric Long COVID. It is a structured pattern recognition and longitudinal tracking framework designed to identify probable pediatric Long COVID through seven interlocking domains: post-infectious temporal architecture, multisystem symptom density, post-exertional pattern architecture, functional and developmental disruption, autonomic and biologic signal integrity, family and school system impact, and access friction with diagnostic delay.
Rather than relying on isolated symptoms or a single clinical encounter, CDF-Peds-LC™ evaluates whether these domains form a coherent post-infectious illness pattern over time. The framework recognizes that pediatric Long COVID frequently presents through fluctuating symptoms, developmental interruption, fragmented healthcare encounters, and changing educational needs that may not be apparent during individual visits. By shifting the unit of analysis from individual symptoms to longitudinal pattern coherence, CDF-Peds-LC™ is designed to support earlier recognition, more consistent clinical assessment, coordinated multidisciplinary care, and improved educational and family support planning.
CDF-Peds-LC™ is not intended to replace physician judgment or formal differential diagnosis. It is intended to make missed recognition less likely, to make functionally meaningful illness easier to document, and to help pediatric systems respond before a child has to become dramatically ill to be taken seriously. It is designed for use across pediatric care, rehabilitation, school support systems, care coordination environments, and research contexts where children are at risk of being mislabeled as anxious, inattentive, oppositional, deconditioned, or overreported rather than being evaluated through a post-viral lens. CDC and AAP materials now explicitly acknowledge that Long COVID can significantly disrupt children’s physical activity, education, and social function, and that school accommodations may be needed when post-COVID symptoms affect attendance, learning, or ordinary activities (CDC, 2025; American Academy of Pediatrics, 2025).
1. Introduction
Long COVID in children has moved from contested anecdote to documented clinical reality, but recognition remains uneven because pediatric systems still tend to reward diseases that are visible, linear, and easy to localize. The 2024 National Academies definition established Long COVID as an infection-associated chronic condition that occurs after SARS-CoV-2 infection and persists for at least three months as a continuous, relapsing and remitting, or progressive disease state affecting one or more organ systems. That definition is important for pediatric work because it validates what many families and clinicians have observed for years: symptoms do not need to be constant, dramatic, or organ-specific to be real, disabling, and medically consequential (National Academies of Sciences, Engineering, and Medicine 2024). WHO has similarly recognized the need for a dedicated pediatric case definition, reinforcing that children and adolescents require their own clinical framing rather than a diluted adult model (World Health Organization 2023).
RECOVER-Pediatrics has further strengthened the field by showing that symptom patterns differ meaningfully across developmental stages. In school-age children and adolescents, the consortium identified empirically derived symptom patterns and research indices that support separate characterization by age group rather than one blended pediatric category. In early childhood, newer RECOVER work found that long COVID symptoms may look different again, reinforcing that a one-size-fits-all screening model across the lifespan is not clinically sensible (Gross et al. 2024; Gross et al. 2025). Broader review work has reached a similar conclusion, showing that pediatric post-COVID condition is heterogeneous and that risk factors, symptom patterns, and prevalence estimates vary significantly depending on study design and case definition (Zimmermann et al. 2024; Alizadeh et al. 2024).
Even with that progress, the practical diagnostic problem remains ugly. Children often do not say “I have orthostatic intolerance” or “I am experiencing post-exertional malaise.” They say their legs feel weird, their brain stopped working, their body is too heavy, everything is too loud, or standing up makes them feel bad. Symptoms may surface most clearly after school, therapy, sports, emotional stress, reinfection, or environmental exposures such as heat or poor air quality. A child may appear stable during a fifteen-minute visit and then spend the evening flattened. Pediatric systems built around point-in-time performance are prone to misread that pattern. Clinical and quality-of-life studies have increasingly shown that pediatric Long COVID affects daily participation, emotional well-being, cognition, stamina, and family functioning in ways that are often more visible longitudinally than during a single encounter (Noij et al. 2025; Luedke et al. 2024).
This is one reason the concept of post-exertional worsening is so important. CDC guidance on ME/CFS recognizes post-exertional malaise as symptom worsening after physical, mental, or emotional exertion, often with delayed onset and prolonged recovery, and also notes that sensory overload can worsen symptoms. That logic is highly relevant to pediatric Long COVID, even if the child never receives an ME/CFS label, because it explains why apparent short-term tolerance can conceal significant physiologic cost (Centers for Disease Control and Prevention 2024a; Centers for Disease Control and Prevention 2024b; Centers for Disease Control and Prevention 2024c). International Delphi consensus work in children and young people has also already identified post-exertional malaise, cardiovascular effects, and school or study change as core outcomes relevant to pediatric post-COVID condition (Seylanova et al. 2024).
CDF-Peds-LC™ was built in response to this gap between illness reality and systems recognition. It assumes that pediatric Long COVID often emerges through timing, multisystem burden, exertional reactivity, autonomic instability, functional decline, and relapse pattern rather than through a single decisive finding. In plain English, the framework is trying to stop systems from looking directly at the elephant in the room and documenting only the rug.
2. Why a Composite Pediatric Framework Is Necessary
A composite framework is necessary because pediatric Long COVID is both heterogeneous and methodologically slippery. Early work such as Molteni et al. in UK school-aged children showed prolonged symptom duration in a subset of infected children, but symptom prevalence estimates have varied sharply across studies depending on study design, controls, and outcome definitions (Molteni et al. 2021). Later work, including controlled pediatric cohort analyses, umbrella reviews, and EHR-based incidence studies, has continued to show meaningful pediatric burden while also confirming that prevalence can swing dramatically based on how post-COVID condition is operationalized (Pereira et al. 2023; Mandel et al. 2025; Alizadeh et al. 2024). That does not mean the condition is unreal. It means the field has been trying to weigh fog with a ruler.
Pediatric systems also fragment the evidence. One clinician sees headaches. Another sees anxiety. A school sees absenteeism and declining stamina. A therapist sees sensory overload and shutdown. A parent sees the full crash pattern but may not be treated as a legitimate longitudinal witness. Without a structured logic model, these pieces remain scattered. The child becomes a pile of disconnected complaints rather than a recognizable post-infectious phenotype. Neuropsychological work has shown that a meaningful subset of pediatric Long COVID patients demonstrate measurable weaknesses in attention and related cognitive domains, while emerging quality-of-life research has found worse quality of life and higher risks of severe anxiety, depression, and sleep problems among affected children compared with peers (Luedke et al. 2024; Noij et al. 2025). Those findings matter because they show that the burden is not only subjective or anecdotal. It is measurable, multidimensional, and functionally consequential.
The need for composite logic becomes even more obvious when autonomic features are considered. Orthostatic intolerance is increasingly recognized in pediatric Long COVID, and recent clinical work using a 10-minute passive standing test found high rates of orthostatic symptoms and abnormal standing responses in children referred for Long COVID evaluation (Morrow et al. 2025). That matters because dizziness, tachycardia, exercise intolerance, nausea, and standing-related symptom worsening can look vague or behavioral unless someone is specifically trained to recognize autonomic dysfunction. In a child who reports fatigue, brain fog, dizziness, nausea, or sudden shutdown after upright activity, the absence of a composite framework invites misclassification.
The need for composite logic becomes even more obvious when social conditions are considered. A recent JAMA Pediatrics analysis of more than 4,500 U.S. children and adolescents found that adverse social determinants, including economic instability and poorer social or community context such as lower social support and higher discrimination, were associated with greater odds of pediatric Long COVID (Rhee et al. 2026). That finding matters because it suggests that risk and recognition are not purely biologic. The environments in which children live, learn, and seek care influence who gets sick, who stays sick, and who gets believed when they are sick.
CDF-Peds-LC™ therefore treats pediatric Long COVID as a pattern-recognition problem under conditions of incomplete information. It does not require hospitalization history. It does not require a dramatic laboratory anomaly. It does not assume that a child without a tidy workup is a child without disease. It assumes instead that pediatric chronic illness often arrives through fragments, and that the ethical task of the system is to assemble those fragments before the child pays the price.
3. Conceptual Basis of CDF-Peds-LC™
The conceptual basis of CDF-Peds-LC™ comes from the convergence of several strands of evidence. First, current formal definitions support a relapsing and multisystem model of Long COVID rather than a narrow symptom-duration model (National Academies of Sciences, Engineering, and Medicine 2024; World Health Organization 2023). Second, pediatric RECOVER studies support age-sensitive characterization and symptom clustering rather than a generic pediatric checklist (Gross et al. 2024; Gross et al. 2025). Third, international consensus work identifies functional and exertional domains as central to pediatric post-COVID outcome measurement (Seylanova et al. 2024). Fourth, school and public-health data now show that Long COVID in children is associated with real-world functional limitation and absenteeism, not simply symptom narration without consequence (Ford et al. 2026; Centers for Disease Control and Prevention 2025).
Within that context, CDF-Peds-LC™ is designed as a recognition scaffold. It asks not merely whether symptoms exist, but whether they hang together in a way that is temporally, physiologically, and functionally consistent with pediatric Long COVID. It is intentionally more interested in pattern architecture than in checklist volume. A child with five disconnected mild complaints is not the same as a child with fewer complaints that clearly worsen after exertion, impair school performance, show autonomic instability, and relapse over time after infection. That logic is aligned not only with RECOVER and consensus work, but also with clinic-based pediatric studies showing recurring fatigue, headache, dizziness, sleep disruption, cognitive difficulty, orthostatic symptoms, and reduced quality of life as core parts of the syndrome (Luedke et al. 2024; Morrow et al. 2025; Noij et al. 2025).
The framework also reflects a basic CYNAERA principle: systems often fail not because the signal is absent, but because the wrong variables are being privileged. Pediatric Long COVID is frequently misread because clinical systems privilege what is immediate, visible, and tidy. CDF-Peds-LC™ instead privileges temporal relationship, multisystem interaction, recovery cost, fluctuation pattern, and functional consequence across settings. That makes it especially suitable for children whose main disability emerges over time rather than in the exam room, and for systems that need to distinguish between isolated symptoms and coherent post-infectious pattern.
4. Scoring Logic: Developmental Pattern Coherence
CDF-Peds-LC™ evaluates pediatric Long COVID through weighted pattern coherence rather than symptom counts alone. The model recognizes that children frequently present with incomplete, fluctuating, or developmentally masked illness. Rather than asking whether a child meets a fixed symptom threshold, the framework evaluates whether multiple domains align into a coherent post-infectious pattern.
The Composite Diagnostic Fingerprint is calculated as:
CDF-Peds-LC(p) = Σ [ wₖ × Dₖ(p) × Sₖ × Uₖ(p) × Mₖ(p) ]
Where:
Dₖ = Domain signal strength (0-1)
Sₖ = Specificity of the domain for pediatric Long COVID
Uₖ = Usability of available clinical information
Mₖ = Modifier accounting for developmental stage, diagnostic delay, masking, access barriers, and referral fragmentation
wₖ = Domain weight (sum = 1.0)
Unlike probability models that require complete datasets, CDF-Peds-LC™ is designed to function despite fragmented information. The score reflects the coherence of the overall illness pattern rather than certainty of diagnosis.
Core Domains
Domain | Weight |
Post-Infectious Temporal Architecture | 15% |
Multisystem Symptom Density | 20% |
Post-Exertional Pattern Architecture | 20% |
Functional & Developmental Disruption | 15% |
Autonomic & Biologic Signal Integrity | 10% |
Family & School System Impact | 10% |
Access Friction & Diagnostic Delay | 10% |
Domain 1: Post-Infectious Temporal Architecture (15%)
Did symptoms emerge following a documented or suspected SARS-CoV-2 infection?
The framework evaluates onset timing, persistence beyond expected recovery, recurrent symptom cycles, and symptom evolution over time.
Domain 2: Multisystem Symptom Density (20%)
Does illness involve multiple physiologic systems?
Representative domains include:
Fatigue
Cognitive dysfunction
Sleep disturbance
Headache
Gastrointestinal symptoms
Orthostatic intolerance
Exercise intolerance
Sensory sensitivity
Temperature intolerance
Respiratory symptoms
The emphasis is not on the number of symptoms but on their organization into a coherent post-viral syndrome.
Domain 3: Post-Exertional Pattern Architecture (20%)
Does physical, cognitive, emotional, or sensory exertion reliably trigger delayed worsening?
Examples include:
Crashes after school
Delayed worsening after sports
Cognitive exhaustion following testing
Delayed symptom escalation after social events
Recovery requiring prolonged rest
Because post-exertional symptom exacerbation represents one of the defining characteristics separating pediatric Long COVID from many alternative explanations, this domain receives one of the highest weights.
Domain 4: Functional & Developmental Disruption (15%)
Has illness interrupted normal developmental progression?
Indicators include:
Declining school attendance
Reduced academic performance
Loss of extracurricular participation
Delayed developmental milestones
Sleep reversal
Reduced independence
Social withdrawal
The framework recognizes developmental interruption as a core marker of pediatric disease burden.
Domain 5: Autonomic & Biologic Signal Integrity (10%)
Are physiologic findings consistent with autonomic dysfunction or post-infectious illness?
Examples include:
Orthostatic intolerance
Tachycardia
Temperature dysregulation
Syncope
Blood pressure instability
Exercise intolerance
Sleep dysregulation
Normal laboratory studies do not reduce this score if the overall physiologic pattern remains coherent.
Domain 6: Family & School System Impact (10%)
Has illness altered the child's educational or family environment?
Examples include:
Parent leaving employment
Frequent medical appointments
Section 504 accommodations
Individualized Education Programs (IEPs)
Homebound instruction
School absences
Reduced family functioning
This domain recognizes that pediatric disability frequently manifests through changes in family systems rather than individual independence.
Domain 7: Access Friction & Diagnostic Delay (10%)
Has healthcare fragmentation contributed to delayed recognition?
Examples include:
Multiple specialist referrals
Repeated reassurance despite progression
Attribution to anxiety alone
Normal screening laboratories despite worsening function
Delayed referral to pediatric specialists
Lack of recognition of post-exertional symptom exacerbation
Original insight: Pediatric Long COVID is frequently delayed not because symptoms are absent, but because developmental changes are interpreted independently rather than assembled into a coherent longitudinal pattern. System failure: Traditional pediatric evaluation treats symptoms as isolated events. CDF-Peds-LC™ evaluates the architecture of illness across time, function, and development.
5. Worked Example: Applying CDF-Peds-LC™ After Clinical Evaluation
The following example continues the patient presented in the Supporting Clinical Evaluation section to demonstrate how laboratory findings, physiologic testing, educational records, and longitudinal history are integrated into the Composite Diagnostic Fingerprint.
Patient Profile
Patient: 13-year-old female
Previously healthy
Competitive swimmer
Excellent academic performance
Mild COVID-19 infection nine months earlier
Persistent fatigue, dizziness, headaches, exercise intolerance, cognitive slowing, and worsening symptoms after school.
Clinical Timeline
Time | Setting | Presentation | System Response |
Month 0 | Acute infection | Mild COVID-19 | Home recovery |
Month 1 | Primary Care | Fatigue and headaches | "Recovery takes time." |
Month 3 | Primary Care | Dizziness, abdominal pain, sleep disruption | CBC, CMP, ESR, CRP, thyroid studies, ferritin, and vitamin testing largely unremarkable. Reassurance provided. |
Month 5 | School | Increasing absences, declining grades, reduced classroom participation | Anxiety and school stress considered. |
Month 6 | Cardiology | Palpitations and dizziness while standing | ECG normal. Symptoms monitored without further evaluation. |
Month 8 | Long COVID Clinic | Persistent post-exertional crashes, exercise intolerance, cognitive slowing, orthostatic symptoms | NASA Lean Test demonstrated orthostatic tachycardia. Comprehensive pediatric Long COVID evaluation initiated. |
Summary of Supporting Evidence
Routine Laboratory Evaluation
CBC: Normal
CMP: Normal
Ferritin: 24 ng/mL (low-normal)
Iron studies: Normal
Vitamin B12: Normal
Folate: Normal
Vitamin D: Mild insufficiency (28 ng/mL)
ESR: Normal
CRP: Normal
TSH / Free T4: Normal
Urinalysis: Normal
Additional Clinical Evidence
NASA Lean Test: Heart rate increase of 42 bpm within 10 minutes of standing
School attendance decreased from 98% to 74%
Teacher reports progressive cognitive slowing and reduced participation
Parent diary documents delayed symptom worsening 12 to 24 hours after school and swimming
Unable to return to competitive athletics
Evaluated by primary care, cardiology, neurology, and behavioral health before referral to a pediatric Long COVID clinic
What the System Saw
Fatigue
Anxiety
School avoidance
Normal bloodwork
Normal ECG
Multiple unrelated complaints
What CDF-Peds-LC™ Recognizes
COVID-19 infection
↓
Persistent multisystem symptoms
↓
Predominantly normal routine laboratory studies
↓
Delayed post-exertional symptom exacerbation
↓
Objective orthostatic tachycardia
↓
Progressive educational and functional decline
↓
Fragmented healthcare encounters
↓
High-coherence pediatric Long COVID pattern
Domain Scoring
Domain | Dₖ | Sₖ | Uₖ | Mₖ | Weight | Contribution |
Post-Infectious Temporal Architecture | 0.90 | 0.85 | 0.90 | 0.90 | 0.15 | 0.093 |
Multisystem Symptom Density | 0.85 | 0.85 | 0.90 | 0.90 | 0.20 | 0.117 |
Post-Exertional Pattern Architecture | 0.95 | 0.95 | 0.90 | 0.95 | 0.20 | 0.154 |
Functional & Developmental Disruption | 0.90 | 0.85 | 0.90 | 0.90 | 0.15 | 0.093 |
Autonomic & Biologic Signal Integrity | 0.80 | 0.85 | 0.85 | 0.90 | 0.10 | 0.052 |
Family & School System Impact | 0.90 | 0.80 | 0.95 | 0.90 | 0.10 | 0.062 |
Access Friction & Diagnostic Delay | 0.90 | 0.85 | 0.90 | 0.95 | 0.10 | 0.065 |
Final Score
0.093 + 0.117 + 0.154 + 0.093 + 0.052 + 0.062 + 0.065 = 0.636
CDF-Peds-LC™ = 0.64
Interpretation
This patient demonstrates a high-confidence pediatric Long COVID pattern. Although routine laboratory studies are almost entirely within normal reference ranges, they successfully exclude many common alternative explanations while objective autonomic testing, longitudinal symptom tracking, caregiver observations, educational decline, and functional impairment produce a highly coherent Composite Diagnostic Fingerprint.
The strongest contributors are post-exertional symptom architecture, multisystem symptom density, developmental disruption, and delayed recognition. Importantly, the largely normal laboratory evaluation does not weaken the score because CDF-Peds-LC™ measures pattern coherence rather than laboratory abnormality.
System Failure
The delay did not occur because evidence was absent. It occurred because the evidence remained fragmented. Primary care documented persistent symptoms. Laboratory testing ruled out common alternative diagnoses. School documented declining performance. Cardiology evaluated palpitations. Parents documented delayed crashes after exertion. Each observation was clinically meaningful, yet no framework existed to integrate them into a unified post-infectious pattern.
CDF-Peds-LC™ assembles these distributed signals into a single longitudinal assessment, allowing recognition to occur before years of continued fragmentation produce more severe disability.
6. Routing Logic: Pattern Strength Determines Urgency
Score | Tier | Recommended Action |
0.00–0.20 | Insufficient Signal | Continue surveillance and reassess if new symptoms emerge. |
0.21–0.35 | Emerging Pattern | Repeat functional assessment, document school impact, monitor progression. |
0.36–0.50 | Probable Pediatric Long COVID | Initiate pediatric evaluation, orthostatic screening, pacing education, and school accommodations. |
0.51–0.70 | High-Confidence Pattern | Prioritize multidisciplinary care, formal educational accommodations, autonomic assessment, and longitudinal monitoring. |
0.71–1.00 | Critical Pattern | Urgent escalation for severe functional decline, nutritional compromise, recurrent syncope, profound post-exertional symptom exacerbation, or inability to safely participate in school or daily activities. |
Original insight: CDF-Peds-LC™ routes children based on longitudinal pattern coherence rather than waiting for complete diagnostic certainty. A child with a score of 0.64 should not remain in a cycle of reassurance. The pattern supports timely multidisciplinary evaluation and coordinated educational support.
System failure: Conventional pediatric care often requires objective confirmation before escalating care. CDF-Peds-LC™ recognizes that fragmentation and developmental masking frequently delay diagnosis, and instead prioritizes coherent patterns that emerge across time, function, and multiple care settings.
7. Optional Signal Overlays
The base domain model can be strengthened through optional overlays that improve sensitivity without becoming mandatory prerequisites. This is deliberate. Many children do not have wearables, specialty testing, or long specialist narratives. A framework that required those inputs would quietly replicate the same access inequities it claims to fix.
One overlay involves autonomic and physiologic signal. This can include standing heart-rate trends, orthostatic symptoms, palpitations, near-syncope, heat intolerance, or activity-linked tachycardia where available. Another overlay involves neurocognitive and behavioral patterning, especially where the child is at risk of being mislabeled with ADHD, anxiety, or oppositionality when the deeper issue is exertion-linked cognitive dysfunction or neuroimmune strain. A third overlay uses caregiver longitudinal logs, validating repeated observations about triggers, crash patterns, sleep changes, appetite shifts, mobility, or sensory burden as legitimate clinical data rather than anecdotal clutter.
School function overlay is especially powerful. School remains one of the clearest natural laboratories for pediatric Long COVID because it places repeated cognitive, sensory, social, and physical demands on the child in a structured environment. Attendance changes, nurse visits, reduced stamina, delayed homework collapse, light or noise intolerance, and fluctuating participation often reveal the condition more clearly than a calm clinic room. CDC’s own recent data linking Long COVID with functional limitation and absenteeism strengthens the rationale for taking those school-based variables seriously.
The final overlay involves access and bias interpretation. This is where CYNAERA’s broader logic architecture becomes especially useful. Children from under-resourced or high bias systems may arrive with more missing data, more delayed referrals, and more inconsistent documentation. CDF-Peds-LC™ allows those realities to inform interpretation rather than treating them as proof against illness. That is not biasing the model. It is correcting for the fact that the world already is.
8. Supporting Clinical Evaluation: Mapping Laboratory and Diagnostic Evidence to CDF-Peds-LC™
CDF-Peds-LC™ is a pattern recognition framework rather than a laboratory algorithm. No single biomarker confirms or excludes pediatric Long COVID, and many affected children have routine laboratory studies within normal reference ranges. Instead, laboratory studies, physiologic testing, educational records, and functional assessments strengthen or contextualize individual CDF domains while the overall Composite Diagnostic Fingerprint is determined by longitudinal pattern coherence.
The purpose of diagnostic testing within CDF-Peds-LC™ is not to "prove" Long COVID. It is to identify physiologic abnormalities, rule out alternative explanations, recognize overlapping conditions, and provide objective evidence that complements the broader clinical pattern.
Domain 1: Post-Infectious Temporal Architecture
Purpose: Establish the relationship between SARS-CoV-2 infection and persistent symptoms.
Supporting evidence may include:
Documented COVID-19 infection (PCR, antigen, or clinical diagnosis)
SARS-CoV-2 antibody testing when clinically appropriate
Medical records documenting symptom onset
Vaccination and infection timeline
Prior viral illnesses and recovery history
Objective evidence is helpful but not required. Many children were infected during periods when testing was unavailable or performed at home.
Domain 2: Multisystem Symptom Density
Purpose: Identify evidence of multisystem involvement while excluding common alternative explanations.
Recommended laboratory evaluation:
Complete Blood Count (CBC)
Comprehensive Metabolic Panel (CMP)
Ferritin
Iron studies
Vitamin B12
Folate
Vitamin D
Thyroid Stimulating Hormone (TSH) with Free T4
Erythrocyte Sedimentation Rate (ESR)
C-Reactive Protein (CRP)
Urinalysis
Additional studies based on presentation:
Celiac screening
Stool calprotectin
Comprehensive nutritional assessment
Normal laboratory findings do not reduce the CDF score. They simply indicate that routine testing has not identified another explanation for the clinical presentation.
Domain 3: Post-Exertional Pattern Architecture
Purpose: Demonstrate delayed physiologic worsening following physical, cognitive, emotional, or sensory exertion.
Supporting evaluation may include:
Structured symptom diary
Activity log
Wearable heart-rate monitoring
Six-minute walk test
Cardiopulmonary Exercise Testing (CPET) when clinically appropriate or in research settings
School attendance patterns
Parent observations documenting delayed crashes
Because post-exertional symptom exacerbation is frequently identified through longitudinal observation rather than laboratory testing, patient and caregiver documentation represents important clinical evidence.
Domain 4: Functional and Developmental Disruption
Purpose: Document the real-world impact of illness on childhood development.
Supporting evidence may include:
School attendance records
Grade changes
Teacher reports
Neuropsychological evaluation
Occupational therapy assessment
Physical therapy evaluation
PROMIS Pediatric functional measures
Activities of daily living assessments
Sports participation history
Extracurricular withdrawal
Developmental disruption often provides stronger evidence of disease burden than isolated laboratory abnormalities.
Domain 5: Autonomic and Biologic Signal Integrity
Purpose: Identify physiologic abnormalities consistent with autonomic dysfunction or post-infectious illness.
Recommended evaluation may include:
NASA Lean Test
Active Stand Test
Orthostatic blood pressure and heart rate measurements
Tilt Table Testing when indicated
Electrocardiogram (ECG)
Holter or ambulatory rhythm monitoring
Echocardiography when clinically appropriate
Pulmonary function testing for persistent respiratory symptoms
Additional specialist evaluation may include:
QSART
Skin biopsy for small fiber neuropathy
Autonomic reflex testing
Objective autonomic abnormalities strengthen this domain but are not required for recognition when the broader pattern is highly coherent.
Domain 6: Family and School System Impact
Purpose: Measure illness burden beyond the individual child.
Supporting documentation may include:
Section 504 Plan
Individualized Education Program (IEP)
Homebound instruction
School nurse visits
Parent work interruption
Caregiver burden assessments
Family-reported symptom logs
Attendance records
Educational accommodation requests
These data provide objective evidence of functional impact that is frequently absent from traditional medical records.
Domain 7: Access Friction and Diagnostic Delay
Purpose: Evaluate whether healthcare system barriers have contributed to delayed recognition.
Supporting indicators include:
Number of healthcare encounters
Emergency department utilization
Number of specialists consulted
Referral delays
Insurance barriers
Geographic barriers to specialty care
Time from symptom onset to recognition
Previous alternative diagnoses
Fragmented medical documentation
This domain recognizes that missing data frequently reflects healthcare access limitations rather than absence of disease.
Interpreting Supporting Evidence
Within CDF-Peds-LC™, diagnostic studies strengthen confidence within individual domains but do not independently establish or exclude the diagnosis.
Finding | Interpretation Within CDF-Peds-LC™ |
Orthostatic tachycardia | Strong support for Domain 5 |
Elevated inflammatory markers | Supportive of Domain 2 but nonspecific |
Normal CBC or CMP | Neutral; does not reduce the score |
Normal MRI | Neutral unless another diagnosis is identified |
Delayed post-exertional crashes documented by caregiver | Strong support for Domain 3 |
Declining school attendance | Strong support for Domains 4 and 6 |
Multiple specialist evaluations without diagnosis | Strong support for Domain 7 |
The Composite Diagnostic Fingerprint is therefore built through the convergence of multiple complementary signals rather than reliance on any single laboratory abnormality. The framework intentionally values longitudinal clinical coherence over isolated test results, recognizing that many children with pediatric Long COVID experience profound functional impairment despite routine diagnostic studies remaining within normal reference ranges.
Worked Example: Interpreting Lab Evidence in CDF-Peds-LC™
Patient Profile
Patient: 13-year-old female
Previously healthy
Competitive swimmer
Mild COVID-19 infection nine months earlier
Persistent fatigue, dizziness, headaches, exercise intolerance, cognitive slowing, and worsening symptoms after school.
Initial Laboratory Evaluation
Test | Result | Interpretation |
CBC | Normal | No evidence of anemia or hematologic disorder |
Comprehensive Metabolic Panel | Normal | No significant electrolyte, renal, or hepatic abnormalities |
Ferritin | 24 ng/mL | Low-normal; may contribute to fatigue but does not explain the full clinical picture |
Iron Studies | Normal | No iron deficiency anemia |
Vitamin B12 | Normal | Nutritional deficiency unlikely |
Folate | Normal | Normal |
Vitamin D | 28 ng/mL | Mild insufficiency; common but nonspecific |
TSH / Free T4 | Normal | Thyroid disease unlikely |
ESR | Normal | No significant systemic inflammatory signal |
CRP | Normal | Normal inflammatory marker |
Urinalysis | Normal | No urinary pathology identified |
Interpretation
Routine laboratory evaluation is largely unremarkable. No alternative diagnosis fully explains the patient's persistent multisystem illness. Within CDF-Peds-LC™, these findings are considered neutral rather than reassuring, because normal screening laboratories are commonly observed in pediatric Long COVID.
Additional Clinical Evaluation
Evaluation | Finding | CDF Domain Supported |
NASA Lean Test | Heart rate increases 42 bpm within 10 minutes of standing | Domain 5: Strong Support |
School Attendance | Attendance decreased from 98% to 74% | Domains 4 & 6 |
Teacher Report | Cognitive slowing and reduced classroom participation | Domain 4 |
Parent Symptom Diary | Delayed symptom crashes 12 to 24 hours after school or exercise | Domain 3 |
Physical Activity | Unable to resume competitive swimming | Domain 4 |
Specialist Timeline | Seen by pediatrician, cardiology, neurology, and behavioral health before Long COVID evaluation | Domain 7 |
Domain Evidence Summary
Domain | Evidence Strength |
Post-Infectious Temporal Architecture | Strong |
Multisystem Symptom Density | Strong |
Post-Exertional Pattern Architecture | Very Strong |
Functional & Developmental Disruption | Very Strong |
Autonomic & Biologic Signal Integrity | Strong |
Family & School System Impact | Moderate to Strong |
Access Friction & Diagnostic Delay | Strong |
Clinical Interpretation
Although routine laboratory studies are almost entirely within normal reference ranges, the broader clinical picture demonstrates a highly coherent pediatric Long COVID pattern. Objective autonomic abnormalities, documented post-exertional symptom exacerbation, declining school performance, reduced physical function, and prolonged post-infectious illness collectively provide substantially stronger diagnostic evidence than routine screening laboratories alone.
This example illustrates one of the central principles of CDF-Peds-LC™: the absence of abnormal routine laboratory findings should not be interpreted as the absence of disease. Instead, laboratory studies should be integrated with physiologic testing, functional assessment, educational data, caregiver observations, and longitudinal symptom evolution to evaluate overall pattern coherence.
Common Mimics
Condition | Why it overlaps | How CDF distinguishes |
Iron deficiency | Fatigue | Doesn't explain PEM or multisystem pattern |
Anxiety | Fatigue, dizziness | Doesn't consistently produce delayed exertional crashes |
Depression | Low activity | Temporal relationship differs |
ADHD | Cognitive problems | Doesn't fluctuate after exertion |
Thyroid disease | Fatigue | Laboratory testing distinguishes |
POTS | Common overlap | Can coexist with pediatric Long COVID |
ME/CFS | Major overlap | Often overlapping phenotype |
Pattern Assembly Table
System Observation | CDF Interpretation |
Mild COVID-19 infection | Post-infectious temporal trigger |
Persistent fatigue, headaches, dizziness | Multisystem symptom density |
Routine laboratory studies largely normal | Common alternative diagnoses less likely |
Delayed crashes after school and swimming | Post-exertional pattern architecture |
NASA Lean Test positive | Autonomic signal integrity |
Declining grades and attendance | Functional and developmental disruption |
Multiple specialists without diagnosis | Access friction and diagnostic delay |
Overall Pattern: High-coherence pediatric Long COVID.
The most informative test in this case was not a blood test. It was the pattern. Routine laboratory studies excluded common alternative explanations, while autonomic testing, longitudinal symptom tracking, and functional decline revealed the underlying architecture of pediatric Long COVID. CDF-Peds-LC™ is designed to assemble these complementary signals into a coherent recognition framework rather than relying on any single diagnostic marker.
9. Educational Integration and School Response
A major strength of CDF-Peds-LC™ is that it translates medical pattern into educational consequence. AAP materials now acknowledge that Long COVID can significantly disrupt physical activity, education, athletic achievement, and social skills development in children and adolescents. CDC likewise states that school administrators, counselors, teachers, and nurses can work with families and healthcare professionals to provide learning or other accommodations for children with Long COVID. This gives strong external grounding for a framework that explicitly bridges diagnosis and school response.
In practice, the framework supports a symptom to function crosswalk. Post exertional worsening may map to reduced workload, pacing, modified PE expectations, and extended time. Cognitive fluctuation may support executive-function accommodations, low stimulation testing environments, and flexible deadlines. Orthostatic symptoms may justify hydration access, rest breaks, salt access where medically appropriate, elevator use, bathroom flexibility, and temperature accommodations. Sleep disruption may support modified schedules or asynchronous learning options.
This section matters because many children with Long COVID are not denied support due to absence of need. They are denied because their needs are not translated into the bureaucratic dialect the school can process. CDF-Peds-LC™ is designed to make that translation cleaner.
10. Clinical, Ethical, and Systems Safeguards
Any framework touching pediatric chronic illness must take ethics seriously, because this is one of the most dangerous zones in medicine for confident nonsense. When children have fluctuating, poorly understood, multisystem illness, the temptation to psychologize what cannot be neatly measured becomes enormous. That temptation can produce real harm, especially when caregiver advocacy is reinterpreted as exaggeration or pathology rather than as adaptation to a child the system keeps failing.
CDF-Peds-LC™ therefore includes several safeguards. It does not treat normal routine tests as dispositive against illness. It does not assume that absence of subspecialty confirmation means absence of disease. It does not permit a behavioral label to automatically outrank post-infectious timing and physiologic pattern. It also does not erase the need for differential diagnosis. Children can have Long COVID and anxiety. They can have Long COVID and ADHD. They can have Long COVID and unrelated conditions. The point is not to replace one reductive monoculture with another. The point is to stop allowing behavioral shorthand to prematurely close the case.
Safeguards built into CDF-Peds-LC™
It requires pattern coherence rather than symptom inflation
It allows repeated reassessment in fluctuating cases
It values function and recovery cost, not just momentary performance
It accepts caregiver and school data as clinically meaningful inputs
It is designed to work even when access barriers have limited formal workup
11. Research, Pilot, and Implementation Applications
CDF-Peds-LC™ is not only a clinical recognition scaffold. It also functions as a research harmonization tool in a field that still struggles with inconsistent pediatric case definitions. Because prevalence estimates and symptom maps depend heavily on methodology, a structured composite framework can help standardize how probable cases are flagged, how phenotypes are tracked longitudinally, and how school or environmental data are integrated into pediatric post-COVID analysis (Molteni et al., 2021; Gross et al., 2024; Mandel et al., 2025).
The framework is especially suitable for pilot use in pediatric primary care networks, post-COVID clinics, school-linked health initiatives, rehabilitation settings, and case-management programs. It can be deployed as a paper form, intake workflow, dashboard layer, caregiver-guided symptom tracker, or school-support tool. That flexibility is not incidental. A framework that only works inside elite digital infrastructure is a framework that will miss exactly the children most likely to be missed.
Over time, the architecture is also adaptable to broader pediatric infection-associated chronic conditions. The same logic that makes CDF-Peds-LC™ useful for Long COVID could support future pediatric composite recognition work in post-infectious dysautonomia, pediatric ME/CFS, and related IACC conditions, provided those adaptations are developed and described transparently rather than smuggled in under one name.
12. Conclusion
CDF-Peds-LC™ was developed because pediatric Long COVID is being missed in ways that are no longer random, isolated, or explainable as simple growing pains within a new field. The pattern of underrecognition has become predictable. Children with post-COVID illness are still being filtered through systems that privilege snapshot assessment over longitudinal pattern recognition, visible dysfunction over fluctuating impairment, and behavioral interpretation over post-infectious clinical reasoning. The result is that many children with real physiologic decline are delayed in recognition, mislabeled in school and healthcare settings, or left to deteriorate until their illness becomes severe enough to satisfy institutional expectations of legitimacy.
The literature now supports several points that should have already shifted practice. Pediatric post-COVID illness exists. It presents differently across developmental stages. It often involves multisystem symptom burden rather than one neatly isolated complaint. It may be relapsing and remitting rather than linear. Exertional and functional changes, including school-related decline, are central to the condition rather than peripheral to it (National Academies of Sciences, Engineering, and Medicine, 2024; Gross et al., 2024; Gross et al., 2025; Seylanova et al., 2024). Taken together, those findings make clear that pediatric Long COVID cannot be responsibly approached through narrow acute-care logic or through overly simplistic questions about whether a child “looks sick” in a single encounter.
At the population level, the burden is already too large to justify institutional delay. CYNAERA Institute’s US-CCUC™ burden correction framework places the likely U.S. pediatric burden at 6 to 10 million children, reflecting the reality that many cases remain relapsing, underdocumented, intermittently disabling, or misclassified through narrower behavioral and diagnostic frameworks (CYNAERA Institute, 2026; Rao et al., 2024). Even the most conservative federal and survey-based estimates point to a major pediatric public health problem. Broader clinical and correction-based modeling only makes visible what frontline families, educators, and patient-informed clinicians have already observed for years: pediatric Long COVID is not rare, and it is not being adequately captured by existing systems.
CDF-Peds-LC™ is CYNAERA's proposed response to that gap. By organizing recognition around post-infectious temporal architecture, multisystem symptom density, post-exertional pattern architecture, functional and developmental disruption, autonomic and biologic signal integrity, family and school system impact, and access friction with diagnostic delay, the framework shifts the diagnostic lens toward the actual architecture of pediatric post-COVID illness rather than isolated symptoms observed during individual clinical encounters. It evaluates how these domains interact over time to produce a coherent pattern of chronic post-infectious disease, allowing clinicians, schools, rehabilitation providers, care coordinators, and researchers to recognize probable pediatric Long COVID earlier, document it more consistently, and respond before prolonged fragmentation leads to unnecessary disability.
This matters because diagnostic failure in pediatrics does not stay confined to the chart. It spills outward into school accommodations, disability support, family burden, therapist interpretation, attendance policy, reimbursement logic, and, in some cases, child welfare or legal misunderstanding. A child who is repeatedly pushed past exertional tolerance may worsen. A child whose cognitive decline is treated as lack of effort may be punished rather than supported. A family that cannot secure documentation may be forced into endless proof-making while the child’s condition grows more entrenched. In that sense, pediatric Long COVID is not only a medical recognition problem. It is a systems design problem.
The purpose of CDF-Peds-LC™ is not to replace full clinical evaluation or erase the need for differential diagnosis. Its purpose is to provide a structured logic framework that makes recognition more accurate, more developmentally appropriate, and less dependent on institutional luck. It is intended to support a standard of care in which longitudinal pattern, functional burden, and recovery cost are treated as valid clinical evidence rather than as afterthoughts. That is particularly important in children whose records are fragmented, whose symptoms are relapsing, or whose access to subspecialty confirmation is limited by geography, poverty, disability, race, language, or institutional bias.
Pediatric Long COVID is not a fringe presentation, a temporary inconvenience, or a problem that becomes meaningful only when a child collapses spectacularly in public. It is already affecting the educational, cognitive, physical, and social lives of millions of children. What remains inconsistent is not the existence of the problem but the willingness of systems to adopt logic capable of recognizing it. CDF-Peds-LC™ is offered as a framework for that next step: a CYNAERA Institute model for making pediatric post-COVID illness more visible, more documentable, and more actionable across the settings where children actually live. A child does not need to fail dramatically to qualify for recognition. A child does not need a catastrophic chart to justify clinical seriousness. When systems wait for unmistakable collapse before acting, that is not rigor. It is delay, and children pay the price for it.
CYNAERA Framework Papers and Core Research Libraries
This paper draws on a defined subset of CYNAERA Institute white papers that establish the methodological and analytical foundations of CYNAERA’s frameworks. These publications provide deeper context on prevalence reconstruction, remission, combination therapies and biomarker approaches. Our Long COVID Library, ME/CFS Library, Lyme Library, Autoimmune Library and CRISPR Remission Library are also in depth resources.
Author’s Note:
All insights, frameworks, and recommendations in this written material reflect the author's independent analysis and synthesis. References to researchers, clinicians, and advocacy organizations acknowledge their contributions to the field but do not imply endorsement of the specific frameworks, conclusions, or policy models proposed herein. This information is not medical guidance.
Patent-Pending Systems
Bioadaptive Systems Therapeutics™ (BST) and affiliated CYNAERA frameworks are protected under U.S. Provisional Patent Application No. 63/909,951. CYNAERA is built as modular intelligence infrastructure designed for licensing, integration, and strategic deployment across health, research, public sector, and enterprise environments.
Licensing and Integration
CYNAERA supports licensing of individual modules, bundled systems, and broader architecture layers. Current applications include research modernization, trial stabilization, diagnostic innovation, environmental forecasting, and population level modeling for complex chronic conditions. Basic licensing is available through CYNAERA Market, with additional pathways for pilot programs, institutional partnerships, and enterprise integration.
About the Author
Cynthia Adinig is the founder of CYNAERA, a modular intelligence infrastructure company that transforms fragmented real world data into predictive insight across healthcare, climate, and public sector risk environments. Her work sits at the intersection of AI infrastructure, federal policy, and complex health system modeling, with a focus on helping institutions detect hidden costs, anticipate service demand, and strengthen planning in high uncertainty environments.
Cynthia has contributed to federal health and data modernization efforts spanning HHS, NIH, CDC, FDA, AHRQ, and NASEM, and has worked with congressional offices including Senator Tim Kaine, Senator Ed Markey, Representative Don Beyer, and Representative Jack Bergman on legislative initiatives related to chronic illness surveillance, healthcare access, and data infrastructure. In 2025, she was appointed to advise the U.S. Department of Health and Human Services and has testified before Congress on healthcare data gaps and system level risk.
She is a PCORI Merit Reviewer, currently advises Selin Lab at UMass Chan, and has co-authored research with Harlan Krumholz, MD, Akiko Iwasaki, PhD, and David Putrino, PhD, including through Yale’s LISTEN Study. She also advised Amy Proal, PhD’s research group at Mount Sinai through its CoRE advisory board and has worked with Dr. Peter Rowe of Johns Hopkins on national education and outreach focused on post-viral and autonomic illness. Her CRISPR Remission™ abstract was presented at CRISPRMED26 and she has authored a Milken Institute essay on artificial intelligence and healthcare.
Cynthia has been covered by outlets including TIME, Bloomberg, Fortune, and USA Today for her policy, advocacy, and public health work. Her perspective on complex chronic conditions is also informed by lived experience, which sharpened her commitment to reforming how chronic illness is understood, studied, and treated. She also advocates for domestic violence prevention and patient safety, bringing a trauma informed lens to her research, systems design, and policy work. Based in Northern Virginia, she brings more than a decade of experience in strategy, narrative design, and systems thinking to the development of cross sector intelligence infrastructure designed to reduce uncertainty, improve resilience, and support institutional decision making at scale.
References
Alizadeh, A. H., Nurchis, M. C., Nittari, G., et al. 2024. Pediatric post COVID-19 condition: an umbrella review of the current evidence. European Journal of Public Health 34(4):cka033.
Centers for Disease Control and Prevention. 2024a. ME/CFS in Children. U.S. Department of Health and Human Services.
Centers for Disease Control and Prevention. 2024b. IOM 2015 Diagnostic Criteria for ME/CFS. U.S. Department of Health and Human Services.
Centers for Disease Control and Prevention. 2024c. Strategies to Prevent Worsening of Symptoms. U.S. Department of Health and Human Services.
Centers for Disease Control and Prevention. 2025. Living with Long COVID. U.S. Department of Health and Human Services.
CYNAERA Institute. 2026. US-CCUC™: Corrected U.S. Pediatric Prevalence Estimate for Long COVID. CYNAERA Institute.
CYNAERA Institute. 2026. CDF-Peds-LC™: Composite Diagnostic Fingerprint Framework for Pediatric Long COVID Recognition, Functional Tracking, and Systems Response. CYNAERA Institute.
Ford, N. D., Simeone, R. M., Pratt, C., & Saydah, S. 2025. Functional limitations and illness-related absenteeism among school-aged children with and without Long COVID, United States, 2022–2023. Emerging Infectious Diseases 31(Suppl).
Gross, R. S., Thaweethai, T., Kleinman, L. C., et al. 2024. Characterizing long COVID in children and adolescents. JAMA 332(11):898–910.
Gross, R. S., Thaweethai, T., Salisbury, A. L., et al. 2025. Characterizing long COVID symptoms during early childhood. JAMA Pediatrics 179(7):781–792.
Luedke, J. C., Vasserman, M., Patel, M., et al. 2024. Neuropsychological functioning of pediatric patients with long COVID: a case series. The Clinical Neuropsychologist 38(8):1855–1872.
Mandel, H., Yoo, Y. J., Allen, A. J., et al. 2025. Long COVID incidence proportion in adults and children between 2020 and 2024: an electronic health record-based study from the RECOVER Initiative. Clinical Infectious Diseases 80(6):1247–1256.
Molteni, E., Sudre, C. H., Canas, L. S., et al. 2021. Illness duration and symptom profile in symptomatic UK school-aged children tested for SARS-CoV-2. The Lancet Child & Adolescent Health 5(10):708–718.
Morrow, A. K., Villatoro, C., Kokorelis, C., Rowe, P. C., & Malone, L. A. 2025. Orthostatic intolerance in children with Long COVID utilizing a 10-minute passive standing test. Clinical Pediatrics 64(3):416–424.
National Academies of Sciences, Engineering, and Medicine. 2024. A Long COVID Definition: A Chronic, Systemic Disease State with Profound Consequences. Washington, DC: National Academies Press.
Noij, L. C. E., Lap, K., van der Pas, M. H. G. M., et al. 2025. Quality of life and mental health in children with long COVID. Communications Medicine 5(1):271.
Pereira, S. M. P., Shafran, R., de Stavola, B. L., et al. 2023. Post-COVID-19 condition at 6 months and outcomes in children and young people after SARS-CoV-2 testing. Archives of Disease in Childhood 108(9):689–696.
Rao, S., Gross, R. S., Mohandas, S., et al. 2024. Postacute sequelae of SARS-CoV-2 in children. Pediatrics 153(3):e2023062570.
Rhee, K. E., Hajagos, J., Gross, R. S., et al. 2026. Social determinants of health and pediatric Long COVID in the US. JAMA Pediatrics.
Seylanova, N., Mesas, A. E., Hjorth, M., et al. 2024. Core outcome measurement set for research and clinical practice in post-COVID-19 condition in children and young people: an international Delphi consensus study. European Respiratory Journal 63(3):2301761.
Vahratian, A., Adjaye-Gbewonyo, D., Lin, J. S., & Saydah, S. 2023. Long COVID in children: United States, 2022. NCHS Data Brief 479:1–8.
World Health Organization. 2023. A Clinical Case Definition for Post COVID-19 Condition in Children and Adolescents by Expert Consensus. World Health Organization.
Comments